Financial Statements · Financial Reporting

AS Bravo Pharmaceuticals

Official identifier 14159974Record date 31 Dec 2022
Estonia

Report

Legal form
AS
Report status
Registered

Dates

Reporting year
2022
Period start
1 Jan 2022
Submitted date
26 Sep 2023

Report

Consolidated
No
Audited
No

Financial metrics

StatementMetricValue
Balance sheetAssets307,383
Balance sheetCash and cash equivalents58
Balance sheetCurrent assets56,781
Balance sheetCurrent liabilities109,217
Balance sheetEquity198,166
Balance sheetShare capital at nominal value163,337
Balance sheetNon-current assets250,602
Balance sheetNon-current liabilities0
Balance sheetRetained earnings (loss) from previous periods-40,649
Kahjumi katmise ettepanekRetained earnings (loss) from previous periods-40,649
Income statement scheme 1Depreciation and impairment of non-current assets-3,638
Income statement scheme 1Labour costs-30,462
Income statement scheme 1Revenue4,775
Income statement scheme 1Annual period profit / loss-100,122
Income statement scheme 1Operating profit (loss)-100,253
Income statement scheme 1Profit (loss) before income tax-100,122
Note: Labour costsEmployees2
Note: Labour costsLabour costs30,462

Linked company

Company: AS Bravo Pharmaceuticals

Source

Estonian e-Business Register Annual Reports open data

View published source

Back to Financial Statements